A total of 563 patients (42.0%) were tested for EGFR mutations (86% of tested patients had adenocarcinomas), with a larger proportion of stage IIIA patients being tested (49.3%) than both stage II (36.7%) and stage IB (38.9%). The gene discussed is EGFR; the disease is adenocarcinoma.